Qiagen N.V.

QGEN

NL0015002CX3

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:02 2025-06-13 pm EDT			5-day change	1st Jan Change
47.11 ^USD	-0.59%		+3.58%	+2.86%

Jun. 10	Qiagen N.V. Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 09:55 AM
Jun. 09	Canatu plc Appoints Nedal Safwat as Chief Development Officer, and President of Canatu Inc, Effective June 9, 2025	CI

Qiagen Acquires Genoox for $70 Million

Published on 05/13/2025 at 03:29

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Qiagen N.V.

Qiagen N.V. Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 09:55 AM	Jun. 10
Canatu plc Appoints Nedal Safwat as Chief Development Officer, and President of Canatu Inc, Effective June 9, 2025	Jun. 09	CI
Tracer Biotechnologies Announces Strategic Partnership with QIAGEN to Advance Blood-Based MRD Testing for Solid Tumors	Jun. 05	CI
QIAGEN NV : Receives a Buy rating from Deutsche Bank	Jun. 03	ZD
Foresight Diagnostics and Qiagen Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma	Jun. 02	CI
Qiagen Enters Partnerships, Expands Portfolio for Minimal Residual Disease Testing in Oncology	Jun. 02	MT
Foresight Diagnostics And Qiagen Announce Strategic Partnership To Advance Development Of Companion Diagnostic Kits For Lymphoma	Jun. 02	RE
QIAGEN NV : Berenberg gives a Buy rating	May. 29	ZD
QIAGEN NV : Receives a Buy rating from DZ Bank	May. 27	ZD
Qiagen Expands Oncology Research Portfolio in Partnership with ID Solutions	May. 22	MT
QIAGEN N.V. Expands Digital PCR Oncology Research Portfolio Through Partnership with ID Solutions	May. 22	CI
Qiagen N.V. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 10:00 AM	May. 14
Qiagen Acquires Genoox for $70 Million	May. 13	MT
Qiagen Acquires Genoox For $70 Million Plus $10 Million In Milestones	May. 12	RE
Qiagen N.V. signed a definitive agreement to acquire Genoox, Ltd. for $80 million.	May. 11	CI
QIAGEN NV : UBS sticks Neutral	May. 09	ZD
QIAGEN : Good start to 2025	May. 08
Qiagen N.V., Q1 2025 Earnings Call, May 08, 2025	May. 08
QIAGEN NV : Gets a Buy rating from Deutsche Bank	May. 08	ZD
Qiagen - H. Rusckowski To Succeed Lawrence A. Rosen As Chairman Of Supervisory Board Following AGM	May. 08	RE
Qiagen Q1 Adjusted Earnings, Revenue Rise; New $500 Million Stock Buyback Planned	May. 07	MT
Earnings Flash (QGEN) QIAGEN Q1 Revenue $483 Million Vs. FactSet Est. $468.9 Million	May. 07	MT
Earnings Flash (QGEN) QIAGEN Q1 Adjusted EPS $0.55 Vs. FactSet Est. $0.50	May. 07	MT
QIAGEN N.V Announces Board Resignations	May. 07	CI

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Employees

5,700

Sector

Biotechnology & Medical Research

Calendar

Jun. 17 - Citi Conference

More about the company